ALCANZA: brentuximab vedotin versus physician's choice in CD30-positive cutaneous T-cell lymphoma
In CD30-expressing mycosis fungoides and primary cutaneous anaplastic large cell lymphoma, the antibody-drug conjugate brentuximab vedotin produced lasting responses in more than half of patients, far more than methotrexate or bexarotene.
Overview
Phase 3 trial of 131 patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large cell lymphoma previously treated with systemic therapy, randomised to brentuximab vedotin or physician's choice of methotrexate or bexarotene.
Objective response lasting at least four months was 56.3 versus 12.5 percent, median progression-free survival 16.7 versus 3.5 months, and peripheral neuropathy occurred in two thirds of brentuximab patients.
- Objective response lasting four months or more: 56.3 percent vs 12.5 percent.
- Median progression-free survival 16.7 vs 3.5 months.
Brentuximab vedotin is a standard for CD30-positive cutaneous T-cell lymphoma requiring systemic therapy, including large cell transformation.
- Peripheral neuropathy in 67 percent, mostly reversible.
- CD30 expression threshold for benefit is low and variable.